Clinical Trials Browser

INDUSTRY × Etoposide × 30 days × Clear all

NCT06077500 2026-05-27

DAREONᵀᴹ-8

Phase 1 Active not recruiting

Small Cell Lung Carcinoma

NCT06132113 2026-05-27

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Phase 1 Recruiting

Neuroendocrine Neoplasms

NCT07544654 2026-05-27

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

Phase 3 Not yet recruiting

Extrapulmonary Neuroendocrine Cancer

NCT04624204 2026-05-26

MK 7339-013

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT07227597 2026-05-26

MK-6070-003

Phase 1/2 Recruiting

Small Cell Lung Cancer Extensive Stage

NCT02632708 2026-05-22

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06564844 2026-05-22

TROPION-Lung12

Phase 3 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT07005128 2026-05-22

DeLLphi-312

Phase 3 Recruiting

Small Cell Lung Carcinoma

NCT07155174 2026-05-18

SEZanne

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT04380636 2026-05-15

MK-7339-012

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07472517 2026-05-12

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

Phase 3 Recruiting

Small Cell Lung Carcinoma

NCT06230224 2026-05-11

OLYMPIA-4

Phase 3 Active not recruiting

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT06646276 2026-05-11

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Phase 3 Recruiting

Small Cell Lung Carcinoma

NCT07296809 2026-05-08

SKB500 Combinations in Patients With Small Cell Lung Cancer

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT03182244 2026-05-05

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

Phase 3 Active not recruiting

276 enrolled 41 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05533775 2026-05-04

iMATRIX GLO

Phase 1/2 Recruiting

Recurrence

NCT05815160 2026-05-04

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Phase 1 Terminated

Recurrence, Small Cell Lung Carcinoma